Wo2018117152a1 google patents delgocitinib?

What is WO2018117152A1, and how does it relate to delgocitinib?

WO2018117152A1 is a patent publication on Google Patents. It describes an invention that includes or is relevant to delgocitinib (a JAK inhibitor candidate). Patent documents like this typically cover one or more of the following: chemical compositions (including specific salts/polymorphs), methods of making the compounds, and/or methods of using them for treating diseases where JAK signaling is implicated.

Because your question names both the publication number and “delgocitinib,” the most direct way to verify the exact connection is to open the publication on Google Patents and check which claims and examples explicitly name delgocitinib (or its chemical descriptors) and what therapeutic indication the claims target.

What exactly should you look for on Google Patents in this document?

In WO2018117152A1, the delgocitinib link will usually show up in:
- The “Claims” section: look for delgocitinib (or its IUPAC/name/structure references) in claim language.
- The “Description” and “Examples”: look for synthesis steps or formulation examples tied to delgocitinib.
- Any “Therapeutic use” paragraphs: look for indications such as inflammatory or immune-mediated diseases.
- The “Assignee” and “Inventor” fields: they indicate who filed it and often align with the development program behind delgocitinib.

Who filed WO2018117152A1, and what does that imply about delgocitinib development?

On Google Patents, the “Assignee” and “Inventors” typically tell you whether the document is from the company that originally developed delgocitinib, a collaborator, or a generic/portfolio filer. That can help you infer whether the patent is aimed at:
- core compound/IP protection (early discovery),
- formulation or dosing approaches (later-life cycle IP),
- or method-of-treatment claims for a particular indication.

How can you confirm the exact delgocitinib compound in the patent text?

Delgocitinib may appear as:
- “delgocitinib” directly, or
- a chemical name,
- a salt form (if claimed),
- or a structural/formula reference (which may require matching to delgocitinib’s known structure).

If you paste the “Abstract” or the relevant claim text from WO2018117152A1 here, I can tell you precisely which claim(s) cover delgocitinib and what the claimed use is.

What are the practical implications of a patent like this for someone researching or licensing delgocitinib?

For research, IP, or licensing, the key issues are:
- whether claims cover the compound itself versus only particular methods/uses,
- whether claims are limited to specific salts, crystalline forms, or formulations,
- and how broad the therapeutic claims are (general JAK-inhibition use vs. a specific disease label).

Those details determine whether the patent is likely to block specific commercialization paths or whether it may leave room around the edges (e.g., for different formulations or indications).

Send the link or text and I’ll extract the delgocitinib details

If you share either:
- the Google Patents URL for WO2018117152A1, or
- the abstract and 1–3 representative claims,

I’ll summarize exactly what the document claims about delgocitinib (compound, salts/formulations, and methods of use) and highlight any parts that look most relevant to freedom-to-operate or scientific comparison.